Cassava Sciences | PTIE - Operating Profit


Cassava Sciences reported $-11.86M in Operating Profit for its fiscal quarter ending in September of 2025.





Operating Profit Change Date
Abbott USD 2.25B 73M Dec/2025
Amgen USD 3.96B 464M Dec/2025
Biogen USD 659.6M 192.2M Sep/2025
Cassava Sciences USD -11.86M 2.23M Sep/2025
Eisai JPY 13.67B 7.07B Sep/2025
Eli Lilly USD 8.39B 1.37B Sep/2025
Geron USD -13.89M 1.43M Sep/2025
J&J USD 5.59B 1.81B Dec/2025
Merck USD 6.24B 318M Dec/2025
Novartis USD 4.5B 363M Sep/2025
Pfizer USD 4.65B 3.99B Dec/2025
Roche Holding CHF 9.56B 3.8B Dec/2025